

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-07083		Serial No.: 10/630,070	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(See back of sheet if Necessary)</small> (37 CFR § 1.98(b))				Applicant: David R. Milich <i>et al.</i>			
				Filing Date: 07/30/2003		Group Art Unit:	
U.S. PATENT DOCUMENTS							
Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
	1	6,518,014	2/11/03	Seifer <i>et al.</i>			
FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS							
		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation
m m	2	WO/019833 A2	12/27/01	PCT			Yes No
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)							
	3	Birkett, U.S. Patent Application No. 20030202982, published 10/30/03					
	4	Birkett, U.S. Patent Application No. 20030185858, published 10/2/03					
	5	Zavala <i>et al.</i> , U.S. Patent Application No. 20030185854, published 10/2/03					
	6	Birkett, U.S. Patent Application No. 20030175863, published 9/18/03					
	7	Birkett, U.S. Patent Application No. 20030138769, published 7/24/03					
	8	Birkett, U.S. Patent Application No. 20030054337, published 3/20/03					
	9	Brown <i>et al.</i> , U.S. Patent Application No. 20030175296, published 9/18/03					
	10	Page <i>et al.</i> , U.S. Patent Application No. 20030198645, published 10/23/03					
Examiner:				Date Considered: Dec. 04, 2004			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-146 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>Several Sheets If Necessary</small> <small>(37 CFR § 1.98(b))</small>		Applicant: David R. Milich <i>et al.</i>		
		Filing Date: 07/30/2003	Group Art Unit: 1645	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
mm	1	Chang <i>et al.</i> , "Phenotypic Mixing between Different Hepadnavirus Nucleocapsid Proteins Reveals C Protein Dimerization To Be <i>cis</i> Preferential," (1994) J. Virol. 5225-5231		
Examiner: <i>m. m. farr</i>	Date Considered: Dec. 01, 2004			
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				



FORM PTO-144 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary)		Applicant: David R. Milich <i>et al.</i>	
(37 CFR § 1.98(b))		Filing Date: 07/30/2003	Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Serial / Patent Number	Issue Date	Applicant / Patentee	Class	Subclass	Filing Date
mm	1	4,683,195	7/28/87	Mullis <i>et al.</i>			
	2	4,683,202	7/28/87	Mullis			
	3	4,965,188	10/23/90	Mullis <i>et al.</i>			
	4	6,602,705	8/5/03	Barnett <i>et al.</i>			
	5	6,406,705	6/18/02	Davis <i>et al.</i>			
	6	6,231,864	5/15/01	Birkett			
	7	4,599,230	7/8/86	Milich <i>et al.</i>			
	8	4,599,231	7/8/86	Milich <i>et al.</i>			
	9	4,683,136	7/8/87	Milich <i>et al.</i>			
	10	5,726,011	3/10/98	Milich <i>et al.</i>			
	11	4,818,527	4/4/89	Thornton <i>et al.</i>			
	12	4,882,145	11/21/89	Thornton <i>et al.</i>			
	13	5,143,726	9/1/92	Thornton <i>et al.</i>			

FOREIGN PATENTS OR PUBLISHED FOREIGN PATENT APPLICATIONS

		Document Number	Publication Date	Country / Patent Office	Class	Subclass	Translation	
							Yes	No
mm	14	WO 02/13765	12/21/02	PCT				
L	15	WO 01/98333 A2	12/27/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

mm	16	Pumpens and Grens (2001) "HBV Core Particles as a Carrier for B Cell/T Cell Epitopes," <i>Intervirology</i> 44:98-114
	17	Jegerlehner <i>et al.</i> "A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses," (2002) <i>Vaccine</i> 20:3104
	18	Anderson and Young, Quantitative Filter Hybridization, <i>in Nucleic Acid Hybridization</i> [1985]
	19	Smith and Waterman (1981) "Comparison of Biosequences," <i>Adv. Appl. Math.</i> 2: 482-489
✓	20	Needleman and Wunsch (1970) "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," <i>J. Mol. Biol.</i> 48: 443-453
✓	21	Pearson and Lipman (1988) "Improved tools for biological sequence comparison," <i>Proc. Natl. Acad. Sci. U.S.A.</i> 85:2444
	22	Sambrook <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Press, NY, pp 9.31-9.58, 1989
	23	Sambrook, <i>et al.</i> , <i>Molecular Cloning: A Laboratory Manual</i> , Cold Spring Harbor Press, NY, pp 7.39-7.52, 1989
	24	GenBank Accession No. NKVLC2 printed 7/16/99
	25	GenBank Accession No. NP_040993 printed 12/8/02

Examiner:	Date Considered:
-----------	------------------

EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
-----------	---

FORM PTO-1449 (Modified)	OCT 31 2003 MAILED	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (37 CFR § 1.98(b))		Applicant: David R. Milich <i>et al.</i>		
		Filing Date: 07/30/2003	Group Art Unit:	

OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)

mm	26	Winter and Milstein (1991) "Man-made antibodies," <i>Nature</i> 349:293-299
	27	Böttcher <i>et al.</i> (1997) "Determination of the fold of the core protein of hepatitis B virus by electron cryomicroscopy," <i>Nature</i> 386:88-91
	28	Conway <i>et al.</i> (1997) "Visualization of a 4-helix bundle in the hepatitis B virus capsid by cryo-electron microscopy," <i>Nature</i> 386:91-94
	29	Salfeld <i>et al.</i> (1989) "Antigenic Determinants and Functional Domains in Core Antigen and e Antigen from Hepatitis B Virus," <i>J Virol.</i> 63:798-808
	30	Schodel <i>et al.</i> (1992) "The Position of Heterologous Epitopes Inserted in Hepatitis B Virus Core Particles Determines Their Immunogenicity," <i>J Virol.</i> 66:106-114
	31	Milich <i>et al.</i> (1995) "The Hepatitis Nucleocapsid as a Vaccine Carrier Moiety," <i>Ann NY Acad Sci.</i> 754:187-201
	32	Pumpens <i>et al.</i> (1995) "Hepatitis B Virus Core Particles as Epitope Carriers," <i>Intervirology</i> 38:63-74
	33	Clarke <i>et al.</i> (1987) "Improved immunogenicity of a peptide epitope after fusion to hepatitis B core protein," <i>Nature</i> 330:381-384
	34	Schodel <i>et al.</i> (1994) "Immunity to Malaria Elicited by Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Protein Epitopes," <i>J Exp Med.</i> 180:1037-1046
	35	Schodel <i>et al.</i> "Immunization with Hybrid Hepatitis B Virus Core Particles Carrying Circumsporozoite Antigen Epitopes Protects Mice Against <i>Plasmodium yoelii</i> Challenge," (1997) <i>Behring Inst Mitt.</i> 114-119
	36	Milich <i>et al.</i> (1997) "Role of B cells in antigen presentation of the hepatitis B core," <i>Proc Natl Acad Sci USA</i> 94:14648-14653
	37	Kratz <i>et al.</i> (1999) "Native display of complete foreign protein domains on the surface of hepatitis B virus capsids," <i>Proc Natl Acad Sci USA</i> 96:1915-1920
	38	Chen <i>et al.</i> (2000) "Nondeletional T-Cell Receptor Transgenic Mice: Model for the CD4+ T-Cell Repertoire in Chronic Hepatitis B Virus Infection," <i>J. Virol.</i> 74:7587-7599
	39	Lazdina <i>et al.</i> (2001) "Molecular Basis for the Interaction of the Hepatitis B Virus Core Antigen with the Surface Immunoglobulin Receptor on Naive B Cells," <i>J Virol.</i> 75:6367-6374
	40	Cao <i>et al.</i> (2001) "Hepatitis B Virus Core Antigen Binds and Activates Naive Human B Cells In Vivo: Studies with a Human PBL-NOD/SCID Mouse Model," <i>J Virol.</i> 75:6359-6366
	41	Anttila <i>et al.</i> (1998) "Avidity of IgG for <i>Streptococcus pneumoniae</i> Type 6B and 23F Polysaccharides in Infants Primed with Pneumococcal Conjugates and Boosted with Polysaccharide or Conjugate Vaccines," <i>J Infect Dis.</i> 177:1614-1621
	42	Arad <i>et al.</i> (2000) "Superantigen antagonist protects against lethal shock and defines a new domain for T-cell activation," <i>Nat Med.</i> 6:414-421
	43	Visvanathan <i>et al.</i> (2001) "Inhibition of Bacterial Superantigens by Peptides and Antibodies," <i>Infect Immunol.</i> 69:875-884
	44	DeVelasco <i>et al.</i> (1994) "Adjuvant Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines," <i>Vaccine</i> 12:1419-1422
	45	Koletzki <i>et al.</i> (1997) "Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments," <i>J Gen Virol.</i> 78:2049-2053
	46	Smiley and Minion (1993) "Enhanced readthrough of opal (UGA) stop codons and production of <i>Mycoplasma pneumoniae</i> P1 epitopes in <i>Escherichia coli</i> ," <i>Gene</i> 134:33-40
	47	GenBank Accession No. NM 009778 printed April 2003
	48	Dempsey <i>et al.</i> (1996) "C3d of Complement as a Molecular Adjuvant: Bridging Innate and Acquired Immunity," <i>Science</i> 271:348-350
	49	Tedder <i>et al.</i> (1994) "The CD19/CD21 signal transduction complex of B lymphocytes," <i>Immunol Today</i> 15:437-442
	50	GenBank Accession No. X65453 printed April 2001
	51	Morris <i>et al.</i> (1999) "Incorporation of an Isoleucine Zipper Motif Enhances the Biological Activity of Soluble CD40L (CD154)," <i>J. Biol. Chem.</i> 274:418-423
	52	Mackay and Browning (2002) "Baff: A Fundamental Survival Factor for B Cells," <i>Nature Reviews Immunology</i> 2:465-475
	53	GenBank Accession No. NM 008479 printed April 2003

Examiner:	Date Considered:
EXAMINER:	Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449 (Modified)			U.S. Department of Commerce Patent and Trademark Office		Attorney Docket No.: VACCINE-07083		Serial No.: 10/630,070	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))			OCT 31 2003 U.S. PATENT & TRADEMARK OFFICE		Applicant: David R. Milich <i>et al.</i>			
					Filing Date: 07/30/2003		Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	54	El mir and Triebel (2000) "A Soluble Lymphocyte Activation Gene-3 Molecule Used as a Vaccine Adjuvant Elicits Greater Humoral and Cellular Immune Responses to Both Particulate and Soluble Antigens," <i>J. Immunol.</i> 164:5583-5589						
	55	Krieg <i>et al.</i> (1995) "CpG motifs in bacterial DNA trigger direct B-cell activation," <i>Nature</i> 374:546-549						
	56	Davis <i>et al.</i> (1998) "CpG DNA is a Potent Enhancer of Specific Immunity in Mice Immunized with Recombinant Hepatitis B Surface Antigen," <i>J. Immunol.</i> 160:870-876						
	57	Fouet <i>et al.</i> (1999) "Bacillus anthracis surface: capsule and S-layer," <i>J Appl Microbiol.</i> 87:251-255						
	58	Paoletti <i>et al.</i> (2002) "Preclinical evaluation of group B streptococcal polysaccharide conjugate vaccines prepared with a modified diphtheria toxin and a recombinant duck hepatitis B core antigen," <i>Vaccine</i> 20:370-376						
	59	Wang <i>et al.</i> (2003) "Construction of designer glycoconjugate vaccines with size-specific oligosaccharide antigens and site-controlled coupling," <i>Vaccine</i> 21:1112-1117						
	60	Bittle <i>et al.</i> (1982) "Protection against foot-and-mouth disease by immunization with a chemically synthesized peptide predicted from the viral nucleotide sequence," <i>Nature</i> 298:30-33						
	61	Van Lierop <i>et al.</i> (1992) "Proliferative lymphocyte responses to foot-and-mouth disease virus and three FMDV peptides after vaccination and immunization with these peptides in cattle," <i>Immunol.</i> 75:406-413						
	62	Wong <i>et al.</i> (2000) "Plasmids Encoding Foot-and-Mouth Disease Virus VP1 Epitopes Elicited Immune Responses in Mice and Swine and protected Swine against Viral Infection," <i>Virol.</i> 278:27-35						
	63	Neirynck <i>et al.</i> (1999) "A universal influenza A vaccine based on the extracellular domain of the M2 protein," <i>Nat Med.</i> 5:1157-1163						
	64	Heinen <i>et al.</i> (2002) "Vaccination of pigs with a DNA construct expressing an influenza virus M2-nucleoprotein fusion protein exacerbates disease after challenge with influenza A virus," <i>J. Gen. Virol.</i> 83:1851-1859						
	65	Pekosz and Lamb (1999) "Cell Surface Expression of Biologically Active Influenza C Virus HEF Glycoprotein Expressed from cDNA," <i>J Virol.</i> 73:8808-8812						
	66	Hughey <i>et al.</i> (1995) "Effects of Antibody to the Influenza A Virus M2 Protein on M2 Surface Expression and Virus Assembly," <i>Virol.</i> 212:411-421						
	67	Zebedee and Lamb (1989) "Growth restriction of influenza A virus by M ₁ protein antibody is genetically linked to the M ₁ protein," <i>Proc Natl Acad Sci USA</i> 86:1061-1065						
	68	Pegram and Slamon (2000) "Biological Rationale for HER2/neu (c-erbB2) as a Target for Monoclonal Antibody Therapy," <i>Semin Oncol.</i> 27:13-19						
	69	Schenk <i>et al.</i> (1999) "Immunization with amyloid- β attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <i>Nature</i> 400:173-177						
	70	Chang (2000) "The pharmacological basis of anti-IgE therapy," <i>Nat Biotechnol.</i> 18:157-162						
	71	Maini and Taylor (2000) "Anti-Cytokine Therapy for Rheumatoid Arthritis," <i>Annu Rev Med.</i> 51:207-229						
	72	Chackerian <i>et al.</i> (2001) "Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies," <i>J Clin Invest.</i> 108:415-423						
	73	Chackerian <i>et al.</i> (1999) "Induction of autoantibodies to mouse CCR5 with recombinant papillomavirus particles," <i>Proc Natl Acad Sci USA</i> 96:2373-2378						
	74	Tall (1993) "Plasma cholesteryl ester transfer protein," <i>Lipid Res.</i> 34:1255-1274						
	75	Barter <i>et al.</i> (1982) "Transfers and exchanges of esterified cholesterol between plasma lipoproteins," <i>Biochem J.</i> 208:1-7						
	76	Whitlock <i>et al.</i> (1989) "Monoclonal Antibody Inhibition of Cholesteryl Ester Transfer Protein Activity in the Rabbit," <i>J Clin Invest.</i> 84:129-137						
	77	Kothari <i>et al.</i> (1997) "Inhibition of cholesterol ester transfer protein by CGS 25159 and changes in lipoproteins in hamsters," <i>Atherosclerosis</i> 128:59-66						
Examiner:				Date Considered:				
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

FORM PTO-1449 Patent and Trademark Office			U.S. Department of Commerce	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Separate Sheet If Necessary)			Attorney Docket No.: VACCINE-07083 Serial No.: 10/630,070	
			OCT 31 2003 TRADEMARK	
			Applicant: David R. Milich <i>et al.</i> Filing Date: 07/30/2003 Group Art Unit:	
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
78	Sugano and Makino (1996) "Changes in Plasma Lipoprotein Cholesterol Levels by Antisense Oligodeoxynucleotides against Cholesteryl Ester Transfer Protein in Cholesterol-fed Rabbits," <i>J Biol Chem.</i> 271:19080-19083			
79	Sugano <i>et al.</i> (1998) "Effect of Antisense Oligonucleotides against Cholesteryl Ester Transfer Protein on the Development of Atherosclerosis in Cholesterol-fed Rabbits," <i>J. Biol. Chem.</i> 273:5033-5036			
80	Agellon <i>et al.</i> (1991) "Reduced High Density Lipoprotein Cholesterol in Human Cholesteryl Ester Transfer Protein Transgenic Mice," <i>J Biol Chem.</i> 266:10796-10801			
81	Herrera <i>et al.</i> (1999) "Spontaneous combined hyperlipidemia, coronary heart disease and decreased survival in Dahl salt-sensitive hypertensive rats transgenic for human cholesteryl ester transfer protein," <i>Nat Med.</i> 5:1383-1389			
82	Koizumi <i>et al.</i> (1985) "Deficiency of Serum Cholesteryl-Ester Transfer Activity in Patients with Familial Hyperalphalipoproteinemia," <i>Atherosclerosis</i> 58:175-186			
83	Rittershaus <i>et al.</i> (2000) "Vaccine-Induced Antibodies Inhibit CETP Activity In Vivo and Reduce Aortic Lesions in a Rabbit Model of Atherosclerosis," <i>Arterioscler Thromb Vasc Biol.</i> 20:2106-2112			
84	Milich <i>et al.</i> (1998) "The Secreted Hepatitis B Precore Antigen Can Modulate the Immune Response to the Nucleocapsid: A Mechanism for Persistence," <i>J. Immunol.</i> 160:2013-2021			
85	Morgan <i>et al.</i> (2000) "A β peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <i>Nature</i> 408:982-985			
86	Smith <i>et al.</i> (2002) "Predicting the failure of amyloid- β vaccine," <i>Lancet</i> 359:1864-1865			
87	Hock <i>et al.</i> (2002) "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease," <i>Nat Med.</i> 8:1270-1275			
88	McLaurin <i>et al.</i> (2002) "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues 4-10 and inhibit cytotoxicity and fibrillogenesis," <i>Nat Med.</i> 8:1263-1269			
89	Rabjohn <i>et al.</i> (2002) "Modification of Peanut Allergen Ara h 3: Effects on IgE Binding and T Cell Stimulation," <i>Int Arch Allergy Immunol.</i> 128:15-23			
90	Beezhold <i>et al.</i> (2001) "Mutational analysis of the IgE epitopes in the latex allergen Hev b 5," <i>J Allergy Clin Immunol.</i> 107:1069-1076			
91	Reese <i>et al.</i> (2001) "Characterization and identification of allergen epitopes: recombinant peptide libraries and synthetic, overlapping peptides," <i>J Chromatogr B Biomed Sci Appl.</i> 756:157-163			
92	Suphioglu <i>et al.</i> (2001) "A novel grass pollen allergen mimotope identified by phage display peptide library inhibits allergen-human IgE antibody interaction," <i>FEBS Lett.</i> 502:46-52			
93	Focke <i>et al.</i> (2001) "Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for allergy vaccination," <i>FASEB J.</i> 15:2042-2044			
94	Karpenko, <i>et. al.</i> (2000) "Insertion of foreign epitopes in HBcAg: how to make the chimeric particle assemble," <i>Amino Acids</i> 18:329-337			
95	Casal <i>et al.</i> (1999) "Parvovirus-Like Particles as Vaccine Vectors," <i>Methods</i> 19:174-186			
96	Sadeyen <i>et al.</i> (2003) "Insertion of a foreign sequence on capsid surface loops of human papillomavirus type 16 virus-like particles reduced their capacity to induce neutralizing antibodies and delineates a conformational neutralizing epitope," <i>Virology</i> 309:32-40			
97	Varsani <i>et al.</i> (2003) "Chimeric Human Papillomavirus Type 16 (HPV-16) L1 Particles Presenting the Common Neutralizing Epitope for the L2 Minor Capsid Protein of HPV-6 and HPV-16," <i>J. Virol.</i> , 77:8386-8393			
98	Rose <i>et al.</i> (1993) "Expression of Human Papillomavirus Type 11 L1 Protein in Insect Cells: In Vivo and In Vitro Assembly of Viruslike Particles," <i>J Virol.</i> 67:1936-1944			
99	Gedvilaitė <i>et al.</i> (2000) "Formation of Immunogenic Virus-like Particles by Inserting Epitopes into Surface-Exposed Regions of Hamster Polyomavirus Major Capsid Protein," <i>Virol.</i> 20:21-35			
100	Pumpens <i>et al.</i> (2002) "Evaluation of HBs, HBc, and frCP Virus-Like Particles for Expression of Human Papillomavirus 16E7 Oncoprotein Epitopes," <i>Intervirol.</i> 45:24-32			
101	Roth (2000) "The yeast Ty virus-like particles," <i>Yeast</i> 16:785-795			
102	Wagner <i>et al.</i> (1996) "Safety and Immunogenicity of Recombinant Human Immunodeficiency Virus-Like Particles in Rodents and Rhesus Macaques," <i>Intervirol.</i> 39:93-103			
Examiner:			Date Considered:	
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1440 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use Several Sheets If Necessary) (37 CFR § 1.98(b))		Oct 31 2003 U.S. Patent & Trademark Office		
		Applicant: David R. Milich <i>et al.</i>		
		Filing Date: 07/30/2003		Group Art Unit:
OTHER DOCUMENTS (Including Author, Title, Date, Relevant Pages, Place of Publication)				
7mm	103	Baumert <i>et al.</i> (1999) "Hepatitis C Virus-like Particles Synthesized in Insect Cells as a Potential Vaccine Candidate," <i>Gastroenterology</i> 117:1397-1407		
	104	Sabara <i>et al.</i> (1991) "Assembly of Double-Shelled Rotaviruslike Particles by Simultaneous Expression of Recombinant VP6 and VP7 Proteins," <i>J. Virol.</i> 65:6994-6997		
	105	Ball <i>et al.</i> (1999) "Recombinant Norwalk Virus-like Particles given Orally to Volunteers" Phase I Study," <i>Gastroenterology</i> 117:40-48		
	106	Brown <i>et al.</i> (1991) "Assembly of Empty Capsids by Using Baculovirus Recombinants Expressing Human Parvovirus B19 Structural Proteins," <i>J. Virol.</i> 65:2702-2706		
	107	Thomsen <i>et al.</i> (1994) "Assembly of Herpes Simplex Virus (HSV) Intermediate Capsids in Insect Cells Infected with Recombinant Baculoviruses Expressing HSV Capsid Proteins," <i>J. Virol.</i> 68:2442-2457		
	108	Urakawa <i>et al.</i> (1989) "Synthesis of Immunogenic, but Non-infectious, Poliovirus Particles in Insect Cells by a Baculovirus Expression Vector," <i>J. Gen. Virol.</i> 70:1453-1463		
	109	Brown <i>et al.</i> (2002) "RNA Bacteriophage Capsid-Mediated Drug Delivery and Epitope Presentation," <i>Intervirol.</i> 45:371-380		
	110	French <i>et al.</i> (1990) "Assembly of Double-Shelled, Viruslike Particles of Bluetongue Virus by the Simultaneous Expression of Four Structural Proteins," <i>J. Virol.</i> 64:5695-5700		
	111	Yamshchikov <i>et al.</i> (1995) "Assembly of SIV Virus-like Particles Containing Envelope Proteins Using a Baculovirus Expression System," <i>Virol.</i> 214:50-58		
	112	Plana-Duran <i>et al.</i> "Oral immunization of rabbits with VP60 particles confers protection against rabbit hemorrhagic disease," (1996) <i>Arch. Virol.</i> 141:1423-1436		
	113	Nikura <i>et al.</i> (2002) "Chimeric Recombinant Hepatitis E Virus-like Particles as an Oral Vaccine Vehicle Presenting Foreign Epitopes," <i>Virol.</i> 293:273-280		
	114	Yao (2003) "Enhancement of mucosal immune responses by chimeric influenza HA/SHIV virus-like particles," <i>Res. Initiat. Treat Action</i> 8:20-21		
	115	Kakker <i>et al.</i> (1999) "Bovine Leukemia Virus Gag Particle Assembly in Insect Cells: Formation of Chimeric Particles by Domain-Switched Leukemia/Lentivirus Gag Polyprotein," <i>Virol.</i> 265:308-318		
	116	Milich <i>et al.</i> (1994) "Extrathymic Expression of the Intracellular Hepatitis B Core Antigen Results in T Cell Tolerance in Transgenic Mice," <i>J. Immunol.</i> 152:455-466		
	117	Milich and McLachlan (1986) "The Nucleocapsid of Hepatitis B Virus Is Both a T-Cell-Independent and a T-Cell-Dependent Antigen," <i>Science</i> 234:1398-1401		
	118	Takashi <i>et al.</i> (1983) "Immunochemical Structure of Hepatitis B e Antigen in the Serum," <i>J Immunol.</i> 130:2903-2911		
	119	Ferrari <i>et al.</i> (1990) "Cellular Immune Response to Hepatitis B Virus-Encoded Antigens in Acute and Chronic Hepatitis B Virus Infection," <i>J Immunol.</i> 145:3442-3449		
	120	Milich <i>et al.</i> (1990) "Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance <i>in utero</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 87:6599-6603		
	121	Calvo-Calle <i>et al.</i> (1997) "Binding of Malaria T Cell Epitopes to DR and DQ Molecules In Vitro Correlates with Immunogenicity In Vivo," <i>J Immunol.</i> 159:1362-1373		
	122	Genbank Accession No. NP_671816 printed 8/3/93		
	123	Genbank Accession No. NKVLC printed 7/16/99		
	124	Genbank Accession No. NP_043683 printed 12/10/02		
	125	Heterobifunctional Cross-linkers, Pierce Chemical Technical Library		
	126	Milich <i>et al.</i> (2002) "Conversion of poorly immunogenic malaria repeat sequences into a highly immunogenic vaccine candidate," <i>Vaccine</i> 20:771-788		
	127	Wynne <i>et al.</i> (1999) "The Crystal Structure of the Human Hepatitis B Virus Capsid," <i>Mol. Cell.</i> 3:771-780		
Examiner:		Date Considered:		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				

FORM PTO-1449 (Modified)		U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No.: VACCINE-07083	Serial No.: 10/630,070
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(Use Separate Sheets If Necessary)</small> <small>(37 CFR § 1.98(b))</small>		Applicant: David R. Milich <i>et al.</i>		
		Filing Date: 07/30/2003	Group Art Unit:	
	128	Hollinger and Dienstag, Chapter 82, Hepatitis B and D Viruses, in <i>Manual of Clinical Microbiology</i> , 7th ed., ASM Press, Washington, D.C., 1999		
	129	Dubovsky, "Creating a Vaccine against Malaria," The Malaria Vaccine Initiative, PATH (Program for Appropriate Technology in Health), January 2001		
	130	Falciparum Malaria MSP1 Workshop, Progress toward MSP1 Vaccine Development and Testing, The Malaria Vaccine Initiative, PATH (Program for Appropriate Technology in Health), December 2000		
	131	Lu <i>et al.</i> (1999) "Immunization of Woodchucks with Plasmids Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen and Surface Antigen Suppresses WHV Infection," <i>J. Virol.</i> 73:281-289		
	132	Menne <i>et al.</i> (1997) "Characterization of T-Cell Response to Woodchuck Hepatitis Virus Core Protein and Protection of Woodchucks from Infection by Immunization with Peptides Containing a T-Cell Epitope," <i>J. Virol.</i> 71:65-74		
	133	Lew <i>et al.</i> (2001) "In Vitro and In Vivo Infectivity and Pathogenicity of the Lymphoid Cell-Derived Woodchuck Hepatitis Virus," <i>J. Virol.</i> 75:1770-1782		
	134	Siegel <i>et al.</i> (2001) "Coadministration of Gamma Interferon with DNA Vaccine Expressing Woodchuck Hepatitis Virus (WHV) Core Antigen Enhances the Specific Immune Response and Protects against WHV Infection," <i>J. Virol.</i> 75:5036-5042		
	135	Birkett, U.S. Patent Application No. 09/930,915, filed: August 15, 2001, published July 24, 2003 as Publication No. 20030138769, and entitled "Immunogenic HBc chimer particles having enhanced stability"		
	136	Brown <i>et al.</i> , U.S. patent publication No. US 20030175296 published Sept. 18, 2003.		
Examiner: <i>m. mft/aw</i>		Date Considered: <i>Dec. 03, 2004</i>		
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.				